Literature DB >> 16438480

Platelets in atherothrombosis.

David A Vorchheimer1, Richard Becker.   

Abstract

Atherosclerosis is a diffuse, systemic disease that affects the coronary, cerebral, and peripheral arterial trees. Disruption of atherosclerotic plaques leads to thrombus formation and arterial occlusion. This unpredictable and potentially life-threatening atherothrombotic sequence underlies clinical events such as angina, myocardial infarction, transient ischemic attacks, and stroke. One of the key components of a clot is the platelet. Although it was previously thought that platelets were relatively inactive cells that merely provided a framework for the attachment of other cells and proteins to mechanically stop bleeding due to injury, it is now known that this is not the case. Platelets secrete and express a large number of substances that are crucial mediators of both coagulation and inflammation. This article reviews the centrality of the platelet in atherothrombosis and briefly looks at the efficacy of antiplatelet agents in preventing and treating cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16438480     DOI: 10.4065/81.1.59

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  24 in total

1.  Inhibition of vascular ectonucleotidase activities by the pro-drugs ticlopidine and clopidogrel favours platelet aggregation.

Authors:  Joanna Lecka; Manjit Singh Rana; Jean Sévigny
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  An αIIbβ3- and phosphatidylserine (PS)-binding recombinant fusion protein promotes PS-dependent anticoagulation and integrin-dependent antithrombosis.

Authors:  Jian Jing; Yanna Sun
Journal:  J Biol Chem       Date:  2019-02-25       Impact factor: 5.157

3.  Platelet-Derived MRP-14 Induces Monocyte Activation in Patients With Symptomatic Peripheral Artery Disease.

Authors:  Rebecca Dann; Tarik Hadi; Emilie Montenont; Ludovic Boytard; Dornaszadat Alebrahim; Jordyn Feinstein; Nicole Allen; Russell Simon; Krista Barone; Kunihiro Uryu; Yu Guo; Caron Rockman; Bhama Ramkhelawon; Jeffrey S Berger
Journal:  J Am Coll Cardiol       Date:  2018-01-02       Impact factor: 24.094

4.  Inflammation and platelet activation in peripheral arterial occlusive disease.

Authors:  Martina Montagnana; Cristiano Fava; Enrico Arosio; Maurizio Degan; Rosa Maria Tommasoli; Sergio De Marchi; Pietro Delva; Roberta Spadaro; Gian Cesare Guidi; Alessandro Lechi; Clara Lechi Santonastaso; Pietro Minuz
Journal:  Int J Angiol       Date:  2007

Review 5.  Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data.

Authors:  Gaurav Sharma; Jeffrey S Berger
Journal:  J Thromb Thrombolysis       Date:  2011-08       Impact factor: 2.300

Review 6.  Triple antiplatelet therapy in acute coronary syndromes.

Authors:  Marco Valgimigli; Monica Minarelli
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

7.  Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation.

Authors:  Jeffrey S Berger; Richard C Becker; Cynthia Kuhn; Michael J Helms; Thomas L Ortel; Redford Williams
Journal:  Thromb Haemost       Date:  2012-12-06       Impact factor: 5.249

Review 8.  Influence of platelet reactivity on clinical outcome of patients with stable coronary artery disease.

Authors:  Annunziata Nusca; Giuseppe Patti; Germano Di Sciascio
Journal:  J Cardiovasc Transl Res       Date:  2013-01-03       Impact factor: 4.132

9.  The relationship of plasma volume, sympathetic tone, and proinflammatory cytokines in young healthy nonpregnant women.

Authors:  Ira M Bernstein; Dana Damron; Adrienne L Schonberg; Reem M Sallam; Robert Shapiro
Journal:  Reprod Sci       Date:  2009-06-16       Impact factor: 3.060

Review 10.  Safety of clopidogrel and aspirin for stroke prevention: implications of the CHARISMA trial.

Authors:  Sean Ruland
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.